Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Neural Regulation01:37

Neural Regulation

43.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

282
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
282

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathogenic POLE-Mutated Endometrial Carcinomas With a Nonultramutated Genome.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2025
Same author

Genome-wide association study reveals shared and distinct genetic architecture of fatty acids and oxylipins in the Hispanic Community Health Study/Study of Latinos.

HGG advances·2024
Same author

Synthesis and biological studies of 2-aminothiophene derivatives as positive allosteric modulators of glucagon-like peptide 1 receptor.

Bioorganic & medicinal chemistry·2024
Same author

Genome-wide association study reveals shared and distinct genetic architecture underlying fatty acid and bioactive oxylipin metabolites in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

medRxiv : the preprint server for health sciences·2024
Same author

Inequalities in birth before arrival at hospital in South West England: a multimethods study of neonatal hypothermia and emergency medical services call-handler advice.

BMJ open·2024
Same author

Metabolic Alterations Caused by Simultaneous Loss of HK2 and PKM2 Leads to Photoreceptor Dysfunction and Degeneration.

Cells·2023
Same journal

Who I am affects what I do.

Practical neurology·2026
Same journal

Recurrent falls while taking clozapine.

Practical neurology·2026
Same journal

Anti-Ma2 encephalitis: when the examination localises beyond MRI.

Practical neurology·2026
Same journal

Oculopharyngeal muscular dystrophy: diagnosis, management and multisystem care.

Practical neurology·2026
Same journal

Neurological signs of possible diagnostic value in the cognitive clinic: past, present and future.

Practical neurology·2026
Same journal

Longitudinally extensive myelitis in neurosarcoidosis.

Practical neurology·2026
See all related articles

Related Experiment Video

Updated: Feb 27, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K

Communication changes in Parkinson's disease.

Nick Miller1

  • 1Speech and Language Sciences, Newcastle University Institute for Ageing, Newcastle upon Tyne, UK.

Practical Neurology
|July 9, 2017
PubMed
Summary
This summary is machine-generated.

Parkinson's disease significantly impacts communication, affecting voice, articulation, and social interaction. Comprehensive assessment and intervention are crucial for managing these pervasive changes.

Keywords:
parkinson's speech language assessment management

More Related Videos

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

26.4K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K

Related Experiment Videos

Last Updated: Feb 27, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

26.4K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K

Area of Science:

  • Neurology
  • Speech-Language Pathology

Background:

  • Parkinson's disease (PD) frequently causes communication impairments, impacting quality of life.
  • Speech changes, including voice and articulation, are common early symptoms.
  • Existing medical and surgical treatments for motor symptoms in PD often do not improve, and can worsen, speech.

Purpose of the Study:

  • To review the nature and impact of communication changes in Parkinson's disease.
  • To explore current assessment approaches for these communication deficits.
  • To outline directions for future intervention strategies.

Main Methods:

  • Literature review synthesizing research on communication in Parkinson's disease.
  • Analysis of the multifaceted nature of speech and language alterations.
  • Examination of the relationship between communication changes and psychosocial well-being.

Main Results:

  • Communication changes in PD are pervasive, extending beyond voice and articulation to include dysprosody, cognitive-linguistic deficits, and pragmatic alterations.
  • Both expressive and receptive communication modalities are affected.
  • These changes significantly impact mood and social participation.

Conclusions:

  • A holistic approach is necessary for evaluating communication challenges in Parkinson's disease.
  • Interventions must address the full spectrum of communication impairments for efficacy.
  • Future research should focus on comprehensive assessment and targeted interventions for PD-related communication disorders.